Self-Administered Nasal Influenza Feasibility Study
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity
of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with
healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group
self-administration of LAIV.
Phase:
Phase 4
Details
Lead Sponsor:
Uniformed Services University of the Health Sciences